Lessons Still To Learn: Cytokinetics’ Omecamtiv Is Over In The US, But FDA Debriefs Could Inform European Strategy
Cytokinetics will not conduct the new trial in heart failure with reduced ejection fraction (HFrEF) required by the FDA’s complete response letter for omecamtiv mecarbil.
You may also be interested in...
Keeping Track: Opdivo, Keytruda Continue Adjuvant Push As Cancer Dominates Recent Applications
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Cytokinetics To Move On From Omecamtiv After FDA’s Complete Response Letter
Company said it will not conduct the additional Phase III trial recommended by the US FDA. Instead, it will focus on its cardiac myosin inhibitor, aficamten, and look for partners to take omecamtiv forward.
US FDA Complete Response Letter Rates Vary With Sponsor Size
Pink Sheet infographic illustrates benefits of big pharma’s resources and experience.